论文部分内容阅读
目的:探讨痰热清联合阿奇霉素治疗支原体肺炎(MP)的临床疗效可行性及安全性。方法:经血清学检测肺炎支原体抗体阳性的肺炎100例,随机分为两组各50例,治疗组采用痰热清联合阿奇霉素治疗,对照组用红霉素治疗,观察治疗前后患者症状,肺部体征的变化及不良反应。结果:治疗组、对照组总有效率分别为96%和78%,两组比较差异具有统计学意义,治疗组明显优于对照组。结论:痰热清联合阿奇霉素治疗支原体肺炎使用安全、简便,疗效好,值得临床推广使用。
Objective: To investigate the feasibility and safety of Tanreqing combined with azithromycin in the treatment of mycoplasma pneumonia (MP). Methods: One hundred patients with pneumonia mycoplasma pneumoniae antibody were detected by serology. They were randomly divided into two groups of 50 patients. The patients in the treatment group were treated with Tanreqing combined with azithromycin. The patients in the control group were treated with erythromycin. The symptoms of the patients before and after treatment were observed. Changes in signs and adverse reactions. Results: The total effective rate of the treatment group and the control group was 96% and 78%, respectively. The differences between the two groups were statistically significant, and the treatment group was significantly better than the control group. Conclusion: Tanreqing combined with azithromycin in the treatment of mycoplasma pneumonia is safe, simple and good curative effect, which is worthy of clinical promotion.